文献速递免疫规划

九价人乳头瘤病毒疫苗在常规使用中接种于男性和女性的安全性

Safety of 9-valent human papillomavirus vaccine administered to males and females in routine use.
PubMed 文献 · Vaccine · 2022-11-14

该回顾性队列研究纳入KPNC≥9岁、2015年10月1日至2017年9月30日接种≥1剂HPV9者215965人,比较接种后风险间期与对照间期的急诊就诊和住院风险,发现18个事件类别比值比显著升高,但未发现新的安全性问题,结果与既往已知安全性特征一致。

要点

  • 研究纳入215965名≥9岁接种≥1剂HPV9者,首次接种中位年龄12-13岁,77%同时接种≥1种其他疫苗。
  • 18个事件类别比值比显著升高,包括皮肤疾病(OR 1.88,95%CI 1.00, 3.53)和定义不清的状况(OR 1.36,95%CI 1.13, 1.64)。
  • 审查后多数发现为既往已知、先于接种或另有原因;37例死亡均与HPV9无关,与背景率一致。

核心结论

  • 未发现与HPV9相关的新安全性问题,结果与既往研究/监测建立的HPV9安全性特征一致。

研究设计与样本

  • 多年度上市后回顾性队列研究,纳入KPNC≥9岁、2015年10月1日至2017年9月30日接种≥1剂HPV9者215965人,其中140628人无既往HPV疫苗接种史。

主要发现

  • 采用条件logistic回归比较接种后风险间期(第0-14天、第1-60天)与对照间期(第61-75天、第61-120天)事件比值比。
  • 18个事件类别比值比显著升高,包括皮肤疾病(OR 1.88,95%CI 1.00, 3.53)和定义不清的状况(OR 1.36,95%CI 1.13, 1.64;该类别包括腹痛、过敏反应、晕厥等)。
  • 审查后多数发现为既往已知、先于接种或另有原因。
  • 接种当天过敏反应和晕厥不常见,但许多可能与接种相关。
  • 37例死亡均不被认为与HPV9相关,且与背景率一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The nine-valent human papillomavirus vaccine (HPV9, Gardasil®9) was licensed in the USA in December 2014. This study was a multiyear post-licensure study to assess HPV9 safety following routine administration. METHODS: This retrospective cohort study compared the risk of emergency department visits and hospitalizations during the interval soon after vaccination with risk during a later interval. Kaiser Permanente Northern California (KPNC) members aged ≥ 9 years who received ≥ 1 HPV9 dose between 10/1/2015-9/30/2017 were included. Outcomes were grouped into predefined diagnostic categories. We compared the odds of events in postvaccination risk intervals (days 0-14, days 1-60) with odds of events during control intervals (days 61-75, days 61-120) using conditional logistic regression. We characterized prespecified events on the day of vaccination (allergic reaction and syncope) and all deaths in the study period. RESULTS: The study included 215,965 individuals receiving ≥ 1 dose of HPV9, of whom 140,628 had no prior HPV vaccination. We observed similar numbers of males and females and racial/ethnic diversity consistent with the underlying population. At first dose median age was 12-13 years and 77% received ≥ 1 concomitant vaccine. Eighteen event categories were significantly elevated, including skin disorders (odds ratio [OR] 1.88, 95% confidence interval [CI] 1.00, 3.53) and ill-defined conditions (OR 1.36, 95% CI 1.13, 1.64; category includes abdominal pain, allergic reactions, syncope, etc.). On review, most findings were previously known, preceded vaccination, or had other causes. Allergic reactions and syncope at vaccination were infrequent but many were potentially related. No deaths (n = 37) were considered related to HPV9 and were consistent with the background rate. CONCLUSIONS: We did not identify new safety concerns related to HPV9. The results are consistent with the HPV9 safety profile as established from previous studies/surveillance. REGISTRATION: European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (EUPAS13151, protocol V503-028).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hansen J, Yee A, Lewis N, et al. Safety of 9-valent human papillomavirus vaccine administered to males and females in routine use. Vaccine. 2022. PMID: 36396513. doi:10.1016/j.vaccine.2022.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。